Details of adverse events with the PrePex device during the study.

<p>Details of adverse events with the PrePex device during the study.</p

Number of adverse events with PrePex circumcision.

<p>Number of adverse events with PrePex circumcision.</p

Figure 1 shows the study flow chart.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100008#pone-0100008-g001" target="_blank">Figure 1</a> shows the study flow chart.</p

Figure 2 shows photographs of selected adverse events with the PrePex device.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100008#pone-0100008-g002" target="_blank">Figure 2a</a>, device self removal with edema and superficial ulceration on day 2 post placement. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100008#pone-0100008-g002" target="_blank">Figure 2b</a>, device self removal with edema on day 1 post placement. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100008#pone-0100008-g002" target="_blank">Figure 2C</a>, wound dehiscence on day 17 post device placement. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100008#pone-0100008-g002" target="_blank">Figure 2d</a>, self removal of the device with edema and necrosis on day 9.</p

General characteristics of FGD participants (n = 92).

<p>F Female. M Male</p

Kaplan-Meier cumulative probabilities of survival from death by feeding group.

<p>Actual visits grouped by the three scheduled visits at one, six and twelve months after birth.</p

Characteristics and behaviors of men who received the PrePex or dorsal slit circumcision.

<p>Characteristics and behaviors of men who received the PrePex or dorsal slit circumcision.</p

Dataset.

Modern contraceptive use has increased globally, but unmet needs persist in low- and middle-income countries. This study in Uganda aimed to examine the prevalence and factors influencing the use of short-acting reversible contraceptives (SARC) like pills and long-term methods such as intrauterine devices. Limited evidence exists on the use of SARC and long-term methods in Uganda. Data from the Africa Medical and Behavioural Sciences Organization (AMBSO) Population Health Surveillance (APHS) in Hoima and Wakiso districts were analysed. Among the 1642 women aged 15–49 years, the prevalence of modern contraceptive use was 30% for SARC, and 18% for long-term method. Women with formal education were three times more likely to use long-term methods than those without formal education, relative risk ratios (RRR), 3.1–3.4, (95%CI 1.2–8.2). Joint decision-making for contraceptive use increased SARC usage, RRR 1.4 (95%CI 1.1–1.8). Urbanization played a role, with women in more urbanized Wakiso district less likely to use any modern contraception, RRR 0.6–0.7 (95%CI 0.5–0.9) compared to those living in the less urbanized Hoima. About half of the women in the study used modern contraceptives and the use of SARC was almost twice that of long-term methods. Increased access to contraception education for all women of reproductive age could significantly improve the use of long-term methods which offer more reliable protection against unintended pregnancies. The findings shed light on the need to strengthen both general and sexuality education to girls and women and to tailor contraception access for all in need, for mobile semi-urban as well as rural women. Well-informed strategies that engage young men and male partners in informed decision-making for contraceptive use could enhance progress.</div

Distribution of socio-demographic characteristics, sexual activity, and decision-making variables by type of contraceptive use among 1635 women in Wakiso and Hoima districts in Uganda in 2020.

Distribution of socio-demographic characteristics, sexual activity, and decision-making variables by type of contraceptive use among 1635 women in Wakiso and Hoima districts in Uganda in 2020.</p

Baseline Maternal and Infant Characteristics.

*<p>Safe water source defined to include boreholes, protected spring or tap water.</p>**<p>61 missing baseline CD4 count</p